Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.55 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.47 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.47 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10126579 | 0.98 | HPGD (0.54) | HPGDAVPR2HTTKDM4EL3MBTL3 | |
| SCHEMBL31202952 | 0.87 | HRH4 (0.53) | HPGDAVPR2HTTL3MBTL1TSHR | |
| SCHEMBL3426385 | 0.87 | HRH4 (0.53) | HPGDAVPR2HTTL3MBTL1TSHR | |
| SCHEMBL17774812 | 0.87 | HPGD (0.55) | HPGDHTTKDM4EL3MBTL3L3MBTL1 | |
| SCHEMBL3400224 | 0.86 | HPGD (0.55) | HPGDHTTKDM4ETSHRGAA | |
| SCHEMBL29451263 | 0.85 | HPGD (0.54) | HPGDHTTKDM4EL3MBTL3L3MBTL1 | |
| SCHEMBL10126592 | 0.85 | HPGD (0.54) | HPGDHTTKDM4EL3MBTL3L3MBTL1 | |
| SCHEMBL4936365 | 0.83 | RAD52 (0.54) | HPGDAVPR2HTTKDM4EKMT2A | |
| SCHEMBL4160200 | 0.83 | HPGD (0.58) | HPGDHTTKDM4EL3MBTL3L3MBTL1 | |
| SCHEMBL22123555 | 0.82 | ALDH1A1 (0.56) | L3MBTL3L3MBTL1KMT2AGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020131627-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | ARRAY BIOPHARMA INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| CN-101981036-B | Pyrrolo [2, 3-D] pyridines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG | 2013-09-04 | — | — | CN | disclosed |
| US-8420657-B2 | Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-04-16 | — | — | US | disclosed |
| CN-101981036-A | Pyrrolo [2, 3-D] pyridines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG | 2011-02-23 | — | — | CN | disclosed |
| EP-2247591-A1 | PYRROLO [2, 3-D]PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS | Novartis AG (CH) | 2010-11-10 | — | — | EP | disclosed |
| US-7732466-B2 | Substituted thiophene carboxamides, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-08 | — | — | US | disclosed |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
| WO-2009098236-A1 | PYRROLO [2, 3-D] PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-08-13 | — | — | WO | disclosed |
| US-7425641-B2 | Carboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2008-09-16 | — | — | US | disclosed |
| US-20080132496-A1 | CARBOXYLIC ACID AMIDES, THE PREPARATION THEREOF, AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2008-06-05 | — | — | US | disclosed |
| WO-2005111014-A1 | SUBSTITUTED THIOPHEN-CARBOXYLIC ACID AMIDES, THE PRODUCTION AND THE USE THEREOF IN THE FORM OF A DRUG | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | WO | disclosed |
| EP-1575925-A1 | NOVEL CARBOXAMIDES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2005-09-21 | — | — | EP | disclosed |
| US-20050065346-A1 | Carboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-03-24 | — | — | US | disclosed |
| WO-2004056784-A1 | NOVEL CARBOXAMIDES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-08 | — | — | WO | disclosed |
| EP-1206446-B1 | CARBOXYLIC ACID AMIDES, THEIR PRODUCTION AND THEIR USE AS DRUGS | BOEHRINGER INGELHEIM PHARMA (DE) | 2004-05-26 | — | — | EP | disclosed |
| EP-1360170-A1 | CARBOXYLIC AMIDES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-11-12 | — | — | EP | disclosed |
| US-20020151595-A1 | Carboxylic acid amides having antithrombotic activity | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-10-17 | — | — | US | disclosed |
| WO-2002062748-A1 | CARBOXYLIC AMIDES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-15 | — | — | WO | disclosed |
| EP-1206446-A1 | CARBOXYLIC ACID AMIDES, THEIR PRODUCTION AND THEIR USE AS DRUGS | Boehringer Ingelheim Pharma KG (DE) | 2002-05-22 | — | — | EP | disclosed |
| WO-2001010823-A1 | CARBOXYLIC ACID AMIDES, THEIR PRODUCTION AND THEIR USE AS DRUGS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132496-A1 | CARBOXYLIC ACID AMIDES, THE PREPARATION THEREOF, AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | F12, F11, F2 | HPGD 1396/4885AVPR2 343/4885HTT 2895/4885 |
| US-20050065346-A1 | Carboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions | F12, F11, F2 | HPGD 870/4885AVPR2 839/4885HTT 4035/4885 |
| US-20020151595-A1 | Carboxylic acid amides having antithrombotic activity | SERPINC1, TFPI, F2 | HPGD 1175/4885AVPR2 1584/4885HTT 1669/4885 |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | HPGD 1215/4885AVPR2 2991/4885HTT 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.